Helixgate

Helixgate

Uncategorized

Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany

Published

on

Plus, news about FDA’s one-day inspections and BioMADE:

🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was established …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

EnGene’s shares crash on updated pivotal bladder cancer data

Published

on

EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects.

The Canadian biotech’s shares {$ENGN} fell 80% Thursday morning after reporting …

Continue Reading

Uncategorized

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

​Read More

Published

on

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

​Read More

Continue Reading

Uncategorized

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

Published

on

The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell therapy’s approval. The news comes a week after the departure of controversial biologics Director Vinay Prasad.

Continue Reading
Advertisement

Trending